Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DSPP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DSPP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DSPP Products |
| Gene Delivery | DSPP Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional overexpression assays. |
View DSPP Products |
| Benchmark Ab | Anti-DSPP Antibody Recombinant positive control for binding and neutralization assays. |
View DSPP Products |
| Validator | DSPP siRNA Set For knockdown verification and target specificity validation. |
View DSPP Products |
| Related Target A | MMP2 Metalloproteinase responsible for DSPP activation and cleavage. Crucial for metastasis studies. |
View MMP2 Products |
| Related Target B | ITGAV Integrin Alpha V, a key cell-surface receptor mediating DSPP-induced migration signaling. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Cleavage Profile | HEK293 Expressed (Native Glycosylation) preserving physiological post-translational modifications. |
| Matrix Metalloproteinase Interference | High Purity (>95%) and Endotoxin Controlled (<1.0 EU/μg) to avoid assay background noise. |
| Lack of Controls | Sequence Verified recombinant benchmark antibodies included |
| False Positives | Validated siRNA included for specificity and knockdown validation |
Live DSPP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DSPP therapeutics is intensifying, with major players shifting focus from traditional bone/dentin regeneration to oncology applications. DSPP (Dentin Sialophosphoprotein) is highly upregulated in multiple aggressive cancers, including oral squamous cell carcinoma (OSCC), breast cancer, lung cancer, and prostate cancer. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific cleavage products (DSP and DPP) and their interaction with cell surface integrins to block tumor metastasis and angiogenesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Startups | Oral Cancer, Breast Cancer Metastasis | Blocking Assay (Need high-purity HEK293-expressed DSPP) |
| siRNA / RNAi | Oncology-focused Biopharma | Advanced Solid Tumors | In vitro knockdown verification (Need validated siRNA sets) |
| Small Molecule Inhibitor | Preclinical Discovery Programs | Bone Metastasis, Osteogenesis Imperfecta | Cleavage inhibition assays (Need sequence-verified MMP-cleavable DSPP) |